Home LiteratureArticle Details
PMID: 56987 Published · ppublish English Journal Article

Enhanced pulmonary toxicity with bleomycin and radiotherapy in oat cell lung cancer.

Cancer ·Vol. 37 ·No. 5 ·1976-05-00 ·Pages 2414-6

Einhorn L, Krause M, Hornback N, Furnas B

Abstract

In a recently completed study, combination chemotherapy consisting of bleomycin, adriamycin, cyclophosphamide, and vincristine was given to 29 patients with oat cell lung cancer. There were no cases of pulmonary fibrosis in these 29 patients. Although several of these patients had prior radiotherapy, none had concomitant radiotherapy and chemotherapy. This same four-drug chemotherapy regimen was combined with concomitant radiotherapy in 13 patients with oat cell lung cancer. There were three cases of fatal pulmonary fibrosis and two other cases of clinically significant pulmonary fibrosis. All five cases of pulmonary fibrosis occurred several weeks after completion of a six-week course of bleomycin (total dosage 90 units). It is concluded that bleomycin cannot be safely administered while patients are receiving radiotherapy to the lung.

MeSH Terms
Bleomycin/toxicity Carcinoma, Small Cell/drug therapy,radiotherapy,therapy Cyclophosphamide/therapeutic use Doxorubicin/therapeutic use Drug Therapy, Combination Humans Lung Neoplasms/drug therapy,radiotherapy,therapy Pulmonary Fibrosis/etiology Radiotherapy/adverse effects Radiotherapy, High-Energy/adverse effects Vincristine/therapeutic use
Chemicals
Bleomycin Vincristine Doxorubicin Cyclophosphamide
Authors & Affiliations
4 authors, click to expand affiliations / ORCID
Einhorn L
Krause M
Hornback N
Furnas B
Article Info
Journal
Cancer
Abbr.
Cancer
ISSN
0008-543X
Published
1976-05-00
Pages
2414-6
Language
English
Region
United States
NLM ID
0374236
Subset
IM
Analysis Services
Analysis Services

Contact

No. 2 Wenbo Road, Zhangqiu District, Jinan, Shandong

Qilu Normal University · Genelibs Bioinformatics Lab

750 Shunhua Rd, Jinan

2F, Bldg F, University Science Park

Tel: 0531-88819269

WeChat Official Account

Follow our WeChat subscription account for real-time updates and the latest in medical and biological research.


Business Email

E-mail: [email protected]